1. Market Research
  2. > Healthcare Market Trends
  3. > CIGNA Corporation - Strategy and SWOT Report

CIGNA Corporation - Strategy and SWOT Report

  • January 2016
  • -
  • MarketLine
  • -
  • 35 pages

Summary

Table of Contents

Search Inside

Introduction

CIGNA Corporation - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on CIGNA Corporation required for business and competitor intelligence needs

- A study of the major internal and external factors affecting CIGNA Corporation in the form of a SWOT analysis

- An in-depth view of the business model of CIGNA Corporation including a breakdown and examination of key business segments

- Intelligence on CIGNA Corporation’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about CIGNA Corporation, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

CIGNA Corporation (CIGNA or 'the company') is a global health services organization engaged in providing medical, dental, disability, life and accident insurance and related products and services. The company offers supplemental health, life and accident insurance products and international health care coverage and services to businesses, governmental and non-governmental organizations and individuals. CIGNA operates in the Americas, Europe, the Middle East, and Asia Pacific. It is headquartered in Bloomfield, Connecticut, and employed 37,200 people as on December 31, 2014. The company recorded revenues of $34,914 million during the financial year ended December 2014 (FY2014), an increase of 7.8% over FY2013. The operating profit of the company was $3,304 million in FY2014, an increase of 51.8% over FY2013. The net profit was $2,102 million in FY2014, an increase of 42.4% over FY2013.

Reasons to Purchase:

- Gain understanding of CIGNA Corporation and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess CIGNA Corporation as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on CIGNA Corporation’s business structure, strategy and prospects

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H2 2016

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Intercellular Adhesion Molecule 1 (Major Group Rhinovirus ...

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease ...

Gastric Ulcers - Pipeline Review, H1 2017

Gastric Ulcers - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • April 2017
  • by Global Markets Direct

Gastric Ulcers - Pipeline Review, H1 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H1 2017, provides an overview of ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.